Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
ACYCLOVIR IN SODIUM CHLORIDE 0.9% PRESERVATIVE FREE vs CARBAGLU
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Acyclovir is a synthetic purine nucleoside analog with inhibitory activity against herpes simplex virus types 1 (HSV-1) and 2 (HSV-2), and varicella-zoster virus (VZV). After intracellular conversion to acyclovir triphosphate, it inhibits viral DNA polymerase, leading to chain termination and viral DNA replication inhibition.
Carbaglu (carbonic anhydrase inhibitor) reduces intraocular pressure by inhibiting carbonic anhydrase in the ciliary processes, thereby decreasing aqueous humor secretion.
Treatment of herpes simplex virus (HSV) infections (genital herpes, herpes labialis, herpes simplex encephalitis),Treatment of varicella-zoster virus (VZV) infections (chickenpox, herpes zoster),Neonatal herpes simplex virus infection,Off-label: Prevention of HSV reactivation in immunocompromised patients, treatment of eczema herpeticum
Adjunctive treatment of elevated intraocular pressure in patients with ocular hypertension or open-angle glaucoma
5 mg/kg IV every 8 hours (or 10 mg/kg IV every 8 hours for varicella-zoster or herpes simplex encephalitis) infused over 1 hour.
100 mg/kg (up to 200 mg/kg) intravenous infusion over 90 minutes, followed by 100 mg/kg/day continuous intravenous infusion; maintenance: 100 mg/kg/day oral divided into 2-4 doses, not to exceed 20 g/day.
Terminal elimination half-life in adults with normal renal function is 2.5-3.3 hours. In anuric patients, half-life extends to approximately 19.5 hours, necessitating dosage adjustment in renal impairment.
Terminal half-life approximately 5.8 hours in adults; prolonged in hepatic impairment (up to 10 hours).
Acyclovir is partially metabolized by aldehyde oxidase and alcohol dehydrogenase to 9-carboxymethoxymethylguanine and other minor metabolites. The majority (62-90%) is excreted unchanged in urine via glomerular filtration and tubular secretion.
Metabolized via hepatic glucuronidation and renal excretion; not extensively metabolized by CYP450 enzymes.
Primarily renal excretion via glomerular filtration and tubular secretion; approximately 62-91% of an administered dose is recovered unchanged in urine. Fecal excretion is minimal (<2%).
Primarily renal excretion (97% unchanged) with minimal biliary/fecal elimination (<3%).
9-33% bound to plasma proteins; binding is concentration-independent and predominantly to albumin.
Negligible (<1% bound to albumin or other plasma proteins).
Approximately 0.7 L/kg, indicating distribution into total body water. Penetrates well into tissues, including cerebrospinal fluid (CSF concentrations ~50% of plasma).
Vd approximately 0.3 L/kg, indicating distribution primarily in extracellular fluid.
Intravenous administration yields 100% bioavailability. Oral bioavailability is 15-30% (not applicable to IV formulation).
Oral bioavailability approximately 30% (range 20-40%) due to first-pass metabolism; IV bioavailability 100%.
Cr Cl >50 m L/min: no adjustment; Cr Cl 25-50 m L/min: 5-10 mg/kg every 12 hours; Cr Cl 10-25 m L/min: 5-10 mg/kg every 24 hours; Cr Cl <10 m L/min: 2.5-5 mg/kg every 24 hours; hemodialysis: give dose after dialysis.
No specific dose adjustment is provided in the manufacturer's labeling; use with caution in renal impairment. GFR <30 m L/min: consider alternative therapy.
No dose adjustment required for hepatic impairment; acyclovir is minimally metabolized by the liver.
No specific adjustment is recommended for hepatic impairment per labeling; monitor transaminases.
Neonates (0-3 months): 10 mg/kg IV every 8 hours for HSV; Infants and children (3 months-12 years): 10 mg/kg IV every 8 hours for HSV, 20 mg/kg IV every 8 hours for VZV; maximum dose 500 mg/m² per dose.
Loading dose: 100 mg/kg (up to 200 mg/kg) IV over 90 minutes; continuous infusion: 100-200 mg/kg/day IV or oral divided q4-6h; maximum 20 g/day.
Elderly patients may have reduced renal function; adjust dose based on Cr Cl and monitor for neurotoxicity (e.g., confusion, hallucinations).
No specific adjustments; use lowest effective dose and monitor renal function given age-related decline.
None.
Sulfonamide derivative; may cause serious, potentially fatal reactions including Stevens-Johnson syndrome, toxic epidermal necrolysis, and agranulocytosis. Discontinue at first sign of rash or other hypersensitivity.
Renal impairment: Dose adjustment required; monitor renal function.,Neurotoxicity: May cause agitation, hallucinations, confusion, seizures (especially in elderly or renally impaired).,Crystalluria: Risk increased with rapid infusion or dehydration; ensure adequate hydration.,Hemolytic uremic syndrome/thrombotic thrombocytopenic purpura (HUS/TTP): Rare but serious, reported in immunocompromised patients.,Pregnancy: Use only if clearly needed (Category B).
Sulfonamide hypersensitivity: may cause serious skin reactions and blood dyscrasias; discontinue if rash or signs of hypersensitivity occur.,May cause metabolic acidosis; use caution in patients with respiratory acidosis, diabetes, or electrolyte disturbances.,May cause drowsiness, dizziness, or blurred vision; caution when driving or operating machinery.
Hypersensitivity to acyclovir, valacyclovir, or any component of the formulation.,Neonates: Use of bacteriostatic water-containing preparations (e.g., benzyl alcohol) is contraindicated.
Hypersensitivity to carbonic anhydrase inhibitors or sulfonamides,Severe renal impairment (Cr Cl <10 m L/min),Adrenocortical insufficiency (Addison's disease),Severe hepatic insufficiency
No specific food interactions. Adequate fluid intake is recommended to prevent renal toxicity. Avoid concurrent use of nephrotoxic substances (e.g., certain NSAIDs, aminoglycosides) without medical supervision.
No specific food interactions; however, patients with urea cycle disorders often require protein restriction. For Carbaglu, avoid acidic beverages (e.g., fruit juice) as they may degrade the drug. Administer with water only.
FDA Pregnancy Category B. No evidence of teratogenicity in animal studies. Limited human data: no increased risk of major birth defects or miscarriage. Risk cannot be ruled out; use only if clearly needed.
First trimester: Limited human data; animal studies show no increased risk of malformations. Second/third trimester: No known fetal harm; can be used for NAGS deficiency.
Acyclovir excreted in breast milk at low levels; M/P ratio unknown. Typical infant dose ~0.6 mg/kg/day (2-3% of maternal IV dose). No adverse effects reported in breastfeeding infants. Compatible with breastfeeding; caution with high maternal doses.
No human data; M/P ratio unknown. Use with caution.
Increased renal clearance and volume of distribution in pregnancy may reduce acyclovir exposure. No dose adjustment routinely recommended; however, higher doses or more frequent dosing may be considered for severe infections. Monitor therapeutic response.
No specific dose adjustments required; monitor ammonia levels to guide therapy.
Acyclovir in sodium chloride 0.9% preservative-free is for IV administration only; do not administer IM or SC. Infuse over at least 1 hour to prevent renal tubular damage. Monitor renal function and adjust dose in renal impairment (Cr Cl <50 m L/min). Ensure adequate hydration (e.g., 500 m L IV fluids per gram acyclovir) to reduce risk of crystalluria. In obese patients, use ideal body weight for dosing. Phlebitis at infusion site is common; rotate sites.
Carbaglu (carglumic acid) is a structural analog of N-acetylglutamate (NAG) and acts as a replacement therapy for N-acetylglutamate synthase (NAGS) deficiency. It is also used for hyperammonemia due to propionic acidemia (PA) or methylmalonic acidemia (MMA). Monitor ammonia levels closely; therapeutic goal is normalization within 24 hours. Administer via oral or nasogastric tube; dissolve tablets in water and administer immediately. Do not mix with acidic fluids (e.g., fruit juice) as stability may be affected. May cause headaches, vomiting, and fever. For NAGS deficiency, lifelong treatment is required. For PA/MMA, use is acute and short-term. Not effective for other urea cycle disorders.
This medication is given intravenously (into a vein) to treat viral infections.,Drink plenty of fluids before and during treatment to prevent kidney problems.,Report any pain, redness, or swelling at the injection site, or any lower back pain.,Tell your healthcare provider if you have kidney disease or are taking other medications that can affect the kidneys.,This drug does not cure herpes infections but helps reduce symptoms and recurrence.
Take Carbaglu exactly as prescribed; do not skip doses.,Dissolve the tablet(s) in a small amount of water (2.5 m L per tablet) and drink immediately. Do not mix with juice or other acidic beverages.,If using a nasogastric tube, ensure the solution is given right after preparation.,Monitor for signs of high ammonia (e.g., lethargy, vomiting, irritability) and report to doctor immediately.,Keep all appointments for blood tests to check ammonia levels.,Store tablets at room temperature (20-25°C), away from moisture and light.,Inform your doctor of all other medications, especially valproic acid (may decrease effectiveness).
"Teriflunomide, the active metabolite of leflunomide, inhibits dihydroorotate dehydrogenase (DHODH), a key enzyme in de novo pyrimidine synthesis, exerting immunomodulatory effects. Acyclovir, an antiviral nucleoside analog, may inhibit organic anion transporter 3 (OAT3)-mediated renal tubular secretion of teriflunomide, leading to increased systemic exposure. Elevated teriflunomide concentrations can potentiate hepatotoxicity, myelosuppression, and immunosuppression, increasing the risk of infections and other adverse effects."
"The serum concentration of Acyclovir can be increased when it is combined with Tizanidine."
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about ACYCLOVIR IN SODIUM CHLORIDE 0.9% PRESERVATIVE FREE vs CARBAGLU, answered by our medical review team.
ACYCLOVIR IN SODIUM CHLORIDE 0.9% PRESERVATIVE FREE is a Electrolyte that works by Acyclovir is a synthetic purine nucleoside analog with inhibitory activity against herpes simplex virus types 1 (HSV-1) and 2 (HSV-2), and varicella-zoster virus (VZV). After intracellular conversion to acyclovir triphosphate, it inhibits viral DNA polymerase, leading to chain termination and viral DNA replication inhibition.. CARBAGLU is a Ammonia Detoxicant that works by Carbaglu (carbonic anhydrase inhibitor) reduces intraocular pressure by inhibiting carbonic anhydrase in the ciliary processes, thereby decreasing aqueous humor secretion.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between ACYCLOVIR IN SODIUM CHLORIDE 0.9% PRESERVATIVE FREE and CARBAGLU depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of ACYCLOVIR IN SODIUM CHLORIDE 0.9% PRESERVATIVE FREE is: 5 mg/kg IV every 8 hours (or 10 mg/kg IV every 8 hours for varicella-zoster or herpes simplex encephalitis) infused over 1 hour.. The standard adult dose of CARBAGLU is: 100 mg/kg (up to 200 mg/kg) intravenous infusion over 90 minutes, followed by 100 mg/kg/day continuous intravenous infusion; maintenance: 100 mg/kg/day oral divided into 2-4 doses, not to exceed 20 g/day.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between ACYCLOVIR IN SODIUM CHLORIDE 0.9% PRESERVATIVE FREE and CARBAGLU in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. ACYCLOVIR IN SODIUM CHLORIDE 0.9% PRESERVATIVE FREE is classified as Category A/B. FDA Pregnancy Category B. No evidence of teratogenicity in animal studies. Limited human data: no increased risk of major birth defects or miscarriage. Risk cannot be ruled out; us. CARBAGLU is classified as Category C. First trimester: Limited human data; animal studies show no increased risk of malformations. Second/third trimester: No known fetal harm; can be used for NAGS deficiency.. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.